Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04764474 · ClinicalTrials.gov registry record · Phase 1
A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH
A Phase 1 study, sponsored by Hutchmed.
- Terminated
- Registry status
- Phase 1
- Development phase
- 46
- Enrollment target
NCT04764474 is a Phase 1 study that was terminated before completion, run by Hutchmed. The registered enrollment target is 46 participants.
The verdict
NCT04764474, a Phase 1 study, was terminated before completion, sponsored by Hutchmed.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 46 participants
- Enrollment target
Study Summary
An open label single-arm clinical trial to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of HMPL-306 in subjects with advanced relapsed, refractory, or resistant hematological malignancies that harbor IDH mutations.
Interventions
- DRUG HMPL-306
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2021-04-12 |
| Est. Completion | 2025-01-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04764474
The ClinicalTrials.gov registry entry for NCT04764474 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hutchmed, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which HMPL-306 is the first listed.
NCT04764474 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04764474 about?
NCT04764474 is a clinical study titled "A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH". An open label single-arm clinical trial to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of HMPL-306 in subjects with advanced relapsed, refractory, or resistant hematological malignancies that harbor IDH mutations.
What is the current status of trial NCT04764474?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2021-04-12. Estimated completion is 2025-01-15.
What interventions are being tested in trial NCT04764474?
The interventions under investigation include: HMPL-306 (DRUG).
Who is sponsoring clinical trial NCT04764474?
This trial is sponsored by Hutchmed, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.